AstraZeneca and Astex Announce New Anti-Cancer Drug Discovery Alliance

CAMBRIDGE, U.K., July 27, 2005 (PRIMEZONE) -- Astex Therapeutics:

 -- AstraZeneca and Astex form their third strategic alliance

 -- Alliance focussed on discovery, development and 
    commercialisation of novel PKB inhibitors for use as anti-cancer 

 -- AstraZeneca will pay Astex an upfront fee of 2.75 million ($5 
    million), research funding, milestone payments of up to 150 
    million ($270 million) and double-digit royalties on commercial 

 -- Astex retains an option on US co-promotion rights and 
    collaborating partners

Full press release attached below:


Contact Data